MI
MIST
Milestone Pharmaceuticals Inc.
$1.27
0.00%
$158.1M
No data for this timeframe.
Vol
Market Cap$158.1M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (83%)
Inst. Holders29 funds
Inst. Value$21.1M
Inst. Activity5 buys / 1 sells
Insider Activity0B / 1S
Insider Net $-$82.5K
SEC Reports4
Press Releases2
Recent Activity
Jun 11, 2026
short_volume
Short Volume: MIST — 58.2% short (0.4M / 0.7M)
Short: 414,391 | Exempt: 750 | TRF Vol: 712,260 | Short Ratio: 58.2% | Off-exchange volume (dark poo
Jun 10, 2026
Insider
Giles Lisa M. was granted 77,000 shares
Director
Jun 10, 2026
Insider
Fischer Seth H. Z. was granted 77,000 shares
Director
Jun 10, 2026
Insider
Duty Stuart was granted 77,000 shares
Director
May 26, 2026
SEC
Milestone Pharmaceuticals' $300M universal shelf registration (S-3, File No. 333-295860) became effective on May 22, 202
EFFECT — Impact 6/10
May 13, 2026
SEC
Milestone Pharmaceuticals filed a $300M universal shelf registration (S-3) on May 13, 2026, including a $100M at-the-mar
S-3 — Impact 6/10
May 13, 2026
SEC
Milestone Pharmaceuticals reported Q1 2026 product revenue of $0.2M from its newly launched CARDAMYST, with ~600 scripts
8-K — Impact 5/10
Inst.
RTW INVESTMENTS, LP — DOUBLED
6,331,001 shares ($7.5M)
Price Targets
$6.33
+398.7% upside
Strong Buy
Current $1.27
Low $2.00
Median $7.00
High $8.00
6 analysts
$2.00
$8.00
Analyst Ratings
3Strong Buy
7Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 14, 2026 | Wells Fargo | MAINTAIN | Overweight → Overweight |
| Jan 6, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.19 ▲ +4.9% | $-0.22 — $-0.17 | 4% YoY | 4 |
| Next Q | $-0.21 ▼ -3.7% | $-0.26 — $-0.18 | -75% YoY | 4 |
| Current FY | $-0.97 ▼ -50.8% | $-1.56 — $-0.74 | -30% YoY | 4 |
| Next FY | $-1.04 ▼ -22.2% | $-1.75 — $-0.70 | -7% YoY | 4 |
Latest Reports
BEARISH
EFFECT
6/10
Milestone Pharmaceuticals' $300M universal shelf registration (S-3, File No. 333-295860) became effective on May 22, 202
May 26, 2026
BEARISH
S-3
6/10
Milestone Pharmaceuticals filed a $300M universal shelf registration (S-3) on May 13, 2026, including a $100M at-the-mar
May 13, 2026
BULLISH
Press
8/10
Milestone Pharmaceuticals (MIST) reported its 2025 financial results alongside a transformative year marked by FDA appro
Mar 20, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| RTW INVESTMENTS, LP | $7.5M | DOUBLED |
| TWO SIGMA INVESTMENTS, LP | $2.8M | DOUBLED |
| GOLDMAN SACHS GROUP INC | $2.4M | — |
| MARSHALL WACE, LLP | $2.3M | DOUBLED |
| Point72 Asset Management, L.P. | $1.3M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 10, 2026 | Giles Lisa | A | $0.00 |
| Jun 10, 2026 | Fischer Seth | A | $0.00 |
| Jun 10, 2026 | Duty Stuart | A | $0.00 |
| Jun 10, 2026 | Wills Robert | A | $0.00 |
| Jun 10, 2026 | TOMSICEK MICHAEL | A | $0.00 |
29 institutional holders with $21.1M total value (17,782,638 shares) as of 2026-Q1. Top holders: RTW, TWO, GOLDMAN. Net buying activity: 5 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | RTW INVESTMENTS, LP | 6,331,001 | $7.5M | 35.7% | DOUBLED +152.6% |
| 2 | TWO SIGMA INVESTMENTS, LP | 2,317,176 | $2.8M | 13.1% | DOUBLED +127.2% |
| 3 | GOLDMAN SACHS GROUP INC | 2,000,025 | $2.4M | 11.3% | — |
| 4 | MARSHALL WACE, LLP | 1,944,530 | $2.3M | 11.0% | DOUBLED +289.8% |
| 5 | Point72 Asset Management, L.P. | 1,085,683 | $1.3M | 6.1% | DOUBLED +125.1% |
| 6 | BALYASNY ASSET MANAGEMENT L.P. | 851,325 | $1.0M | 4.8% | — |
| 7 | TORONTO DOMINION BANK | 750,000 | $892.5K | 4.2% | — |
| 8 | MORGAN STANLEY | 724,141 | $861.7K | 4.1% | TRIM -73.7% |
| 9 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 519,046 | $617.7K | 2.9% | — |
| 10 | Aptus Capital Advisors, LLC | 280,250 | $333.5K | 1.6% | ADD +25.2% |
| 11 | CITADEL ADVISORS LLC | 196,696 | $234.1K | 1.1% | — |
| 12 | GROUP ONE TRADING LLC | 129,764 | $154.4K | 0.7% | TRIM -33.5% |
| 13 | RENAISSANCE TECHNOLOGIES LLC | 129,705 | $154.3K | 0.7% | — |
| 14 | CITADEL ADVISORS LLC | 113,700 | $135.3K | 0.6% | — |
| 15 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 110,100 | $131.0K | 0.6% | — |
| 16 | Invesco Ltd. | 41,356 | $49.2K | 0.2% | ADD +88.9% |
| 17 | CITADEL ADVISORS LLC | 36,300 | $43.2K | 0.2% | — |
| 18 | Mariner, LLC | 30,830 | $36.7K | 0.2% | DOUBLED +127.3% |
| 19 | RAYMOND JAMES FINANCIAL INC | 26,600 | $31.7K | 0.2% | ADD +30.1% |
| 20 | NATIONAL BANK OF CANADA /FI/ | 23,500 | $28.0K | 0.1% | ADD +25.7% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | DOUBLED | 2,506,102 | 6,331,001 | +152.6% | $7.5M | 2026-Q1 |
| Point72 Asset Management, L.P. | DOUBLED | 482,355 | 1,085,683 | +125.1% | $1.3M | 2026-Q1 |
| GROUP ONE TRADING LLC | TRIM | 195,099 | 129,764 | -33.5% | $154.4K | 2026-Q1 |
| Invesco Ltd. | ADD | 21,893 | 41,356 | +88.9% | $49.2K | 2026-Q1 |
| NATIONAL BANK OF CANADA /FI/ | ADD | 18,700 | 23,500 | +25.7% | $28.0K | 2026-Q1 |
| Rockefeller Capital Management L.P. | DOUBLED | 1,700 | 12,500 | +635.3% | $14.9K | 2026-Q1 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | TRIM | 6,976,000 | 2,810,037 | -59.7% | $5.7M | 2025-Q4 |
| MARSHALL WACE, LLP | DOUBLED | 425,028 | 1,656,821 | +289.8% | $3.3M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 666,551 | 1,514,461 | +127.2% | $3.1M | 2025-Q4 |
| MORGAN STANLEY | TRIM | 2,969,067 | 781,875 | -73.7% | $1.6M | 2025-Q4 |
| Aptus Capital Advisors, LLC | ADD | 210,200 | 263,200 | +25.2% | $531.7K | 2025-Q4 |
| GROUP ONE TRADING LLC | DOUBLED | 7,022 | 195,099 | +2678.4% | $394.1K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 16,052 | 841 | -94.8% | $1.7K | 2025-Q4 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | NEW | — | 6,976,000 | — | $14.0M | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 820,421 | 2,969,067 | +261.9% | $5.9M | 2025-Q3 |
| Mariner, LLC | DOUBLED | 11,000 | 25,000 | +127.3% | $50.0K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 8 | 16,052 | +200550.0% | $32.1K | 2025-Q3 |
| GROUP ONE TRADING LLC | NEAR_EXIT | 31,616 | 7,022 | -77.8% | $14.0K | 2025-Q3 |
| UBS Group AG | DOUBLED | 111,523 | 322,648 | +189.3% | $625.9K | 2025-Q2 |
| RAYMOND JAMES FINANCIAL INC | ADD | 33,235 | 43,235 | +30.1% | $83.9K | 2025-Q2 |
| ROYAL BANK OF CANADA | DOUBLED | 10,000 | 35,600 | +256.0% | $69.0K | 2025-Q2 |
| Walleye Capital LLC | NEAR_EXIT | 91,920 | 15,109 | -83.6% | $29.3K | 2025-Q2 |
| CITIGROUP INC | NEAR_EXIT | 329 | 2 | -99.4% | $2.00 | 2025-Q1 |
| MORGAN STANLEY | ADD | 918,312 | 1,289,141 | +40.4% | $3.0M | 2024-Q4 |
| NATIONAL BANK OF CANADA /FI/ | DOUBLED | 7,100 | 18,700 | +163.4% | $44.1K | 2024-Q4 |
11 unique insiders with 22 transactions. Net insider value: -$82.5K ($0.00 bought, $82.5K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 10, 2026 | Giles Lisa M. | Director | AWARD | 77,000 | — | — |
| Jun 10, 2026 | Fischer Seth H. Z. | Director | AWARD | 77,000 | — | — |
| Jun 10, 2026 | Duty Stuart | Director | AWARD | 77,000 | — | — |
| Jun 10, 2026 | Wills Robert James | Director | AWARD | 77,000 | — | — |
| Jun 10, 2026 | TOMSICEK MICHAEL JOHN | Director | AWARD | 77,000 | — | — |
| Jun 10, 2026 | Saik Andrew | Director | AWARD | 77,000 | — | — |
| Apr 16, 2026 | Oliveto Joseph | President and CEO | SELL | 36,500 | $2.26 | $82.5K |
| Feb 2, 2026 | Bharucha David | Chief Medical Officer | AWARD | 204,000 | — | — |
| Feb 2, 2026 | Oliveto Joseph | President and CEO | AWARD | 679,000 | — | — |
| Feb 2, 2026 | Nelson Jeffrey Edward | Chief Operating Officer | AWARD | 204,000 | — | — |
| Feb 2, 2026 | Muller Lorenz | Chief Commercial Officer | AWARD | 204,000 | — | — |
| Feb 2, 2026 | Hasija Amit | CFO & EVP of Corp. Development | AWARD | 204,000 | — | — |
| Feb 2, 2026 | Oliveto Joseph | President and CEO | AWARD | 679,000 | — | — |
| Feb 2, 2026 | Oliveto Joseph | President and CEO | AWARD | 453,000 | — | — |
| Feb 2, 2026 | Bharucha David | Chief Medical Officer | AWARD | 204,000 | — | — |
| Feb 2, 2026 | Bharucha David | Chief Medical Officer | AWARD | 136,000 | — | — |
| Feb 2, 2026 | Nelson Jeffrey Edward | Chief Operating Officer | AWARD | 204,000 | — | — |
| Feb 2, 2026 | Nelson Jeffrey Edward | Chief Operating Officer | AWARD | 136,000 | — | — |
| Feb 2, 2026 | Hasija Amit | CFO & EVP of Corp. Development | AWARD | 204,000 | — | — |
| Feb 2, 2026 | Hasija Amit | CFO & EVP of Corp. Development | AWARD | 136,000 | — | — |
| Feb 2, 2026 | Muller Lorenz | Chief Commercial Officer | AWARD | 204,000 | — | — |
| Feb 2, 2026 | Muller Lorenz | Chief Commercial Officer | AWARD | 136,000 | — | — |
4 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 0 mixed, 2 neutral. Avg impact: 5.5/10.
BEARISH
EFFECT
6/10
Milestone Pharmaceuticals' $300M universal shelf registration (S-3, File No. 333-295860) became effe
May 26, 2026
BEARISH
S-3
6/10
Milestone Pharmaceuticals filed a $300M universal shelf registration (S-3) on May 13, 2026, includin
May 13, 2026
NEUTRAL
8-K
5/10
Milestone Pharmaceuticals reported Q1 2026 product revenue of $0.2M from its newly launched CARDAMYS
May 13, 2026
NEUTRAL
PRESS-RELEASE
5/10
Milestone Pharmaceuticals reported Q1 2026 results with first-ever product revenue of $0.2M from CAR
May 13, 2026
Current analyst consensus: Strong Buy (83% buy). Based on 12 analysts: 3 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$6.33 mean target
+398.7% upside
Strong Buy (3.00)
$2.00 Low
$8.00 High
| Metric | Value |
|---|---|
| Current Price | $1.27 |
| Target Low | $2.00 |
| Target Mean | $6.33 |
| Target Median | $7.00 |
| Target High | $8.00 |
| # Analysts | 6 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.19 | $-0.22 | $-0.17 | 3.8% | +4.9% | 1↑ 2↓ | $0.0B | 0.0% | 4 |
| Next Q 2026-09-30 |
$-0.21 | $-0.26 | $-0.18 | -75.0% | -3.7% | 1↑ 2↓ | $0.0B | 0.0% | 4 |
| Current FY 2026-12-31 |
$-0.97 | $-1.56 | $-0.74 | -29.7% | -50.8% | 0↑ 2↓ | $0.0B | 362.1% | 4 |
| Next FY 2027-12-31 |
$-1.04 | $-1.75 | $-0.70 | -7.5% | -22.2% | 0↑ 3↓ | $0.0B | 313.3% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.193 | |
| 7d ago | $-0.212 | +0.020 |
| 30d ago | $-0.203 | +0.010 |
| 60d ago | $-0.240 | +0.047 |
| 90d ago | $-0.240 | +0.047 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 14, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Jan 6, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 7 | 2 | 0 | 0 | 83% | |
| May 1, 2026 | 3 | 7 | 2 | 0 | 0 | 83% | |
| Apr 1, 2026 | 2 | 7 | 2 | 0 | 0 | 82% | |
| Mar 1, 2026 | 2 | 7 | 2 | 0 | 0 | 82% | |
| Feb 1, 2026 | 2 | 7 | 2 | 0 | 0 | 82% | |
| Jan 1, 2026 | 2 | 7 | 2 | 0 | 0 | 82% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
Recent Reddit Threads
Milestone pharmaceuticals (MIST)
▲ 1
💬 0
⚡ 0.5
Milestone pharmacuitcals( MIST)
▲ 1
💬 0
⚡ 0.5
Jun 11, 2026
short_volume
Short Volume: MIST — 58.2% short (0.4M / 0.7M)
Short: 414,391 | Exempt: 750 | TRF Vol: 712,260 | Short Ratio: 58.2% | Off-exchange volume (dark pool + OTC)
Jun 10, 2026
short_volume
Short Volume: MIST — 55.5% short (0.3M / 0.5M)
Short: 300,490 | Exempt: 87 | TRF Vol: 541,774 | Short Ratio: 55.5% | Off-exchange volume (dark pool + OTC)
Jun 8, 2026
short_volume
Short Volume: MIST — 64.6% short (0.6M / 1.0M)
Short: 630,383 | Exempt: 13,472 | TRF Vol: 975,882 | Short Ratio: 64.6% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
short_volume
Short Volume: MIST — 70.1% short (0.8M / 1.2M)
Short: 816,635 | Exempt: 0 | TRF Vol: 1,165,620 | Short Ratio: 70.1% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: MIST — 61.4% short (0.4M / 0.7M)
Short: 422,809 | Exempt: 2,995 | TRF Vol: 688,903 | Short Ratio: 61.4% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: MIST — 61.8% short (0.5M / 0.8M)
Short: 483,796 | Exempt: 0 | TRF Vol: 783,247 | Short Ratio: 61.8% | Off-exchange volume (dark pool + OTC)
May 27, 2026
short_volume
Short Volume: MIST — 67.8% short (1.0M / 1.4M)
Short: 972,461 | Exempt: 0 | TRF Vol: 1,434,364 | Short Ratio: 67.8% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: MIST — 61.5% short (0.4M / 0.6M)
Short: 395,206 | Exempt: 2,330 | TRF Vol: 642,720 | Short Ratio: 61.5% | Off-exchange volume (dark pool + OTC)
May 14, 2026
other
Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
<p align="justify">MONTREAL and CHARLOTTE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Milestone<sup>® </sup>Pharmaceuticals Inc. (Nasdaq: MIST), a bioph
May 13, 2026
earnings
Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update
<p align="justify">MONTREAL and CHARLOTTE, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- Milestone<sup>®</sup> Pharmaceuticals Inc. (Nasdaq: MIST) a biopha
May 13, 2026
earnings_calendar
MIST Q1 2026 Earnings Scheduled — 2026-05-13
May 11, 2026
short_volume
Short Volume: MIST — 58.5% short (0.3M / 0.6M)
Short: 330,044 | Exempt: 1,927 | TRF Vol: 564,045 | Short Ratio: 58.5% | Off-exchange volume (dark pool + OTC)
May 7, 2026
short_volume
Short Volume: MIST — 83.6% short (0.7M / 0.8M)
Short: 667,617 | Exempt: 0 | TRF Vol: 798,262 | Short Ratio: 83.6% | Off-exchange volume (dark pool + OTC)
May 5, 2026
short_volume
Short Volume: MIST — 56.3% short (0.4M / 0.8M)
Short: 437,075 | Exempt: 0 | TRF Vol: 776,773 | Short Ratio: 56.3% | Off-exchange volume (dark pool + OTC)
Apr 21, 2026
short_volume
Short Volume: MIST — 55.2% short (0.6M / 1.1M)
Short: 586,394 | Exempt: 0 | TRF Vol: 1,061,874 | Short Ratio: 55.2% | Off-exchange volume (dark pool + OTC)